Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours.
Affiliation
The Christie Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, United KingdomIssue Date
2016-02
Metadata
Show full item recordCitation
Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours. 2016, 54:169-71 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2015.10.062PubMed ID
26739580Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2015.10.062
Scopus Count
Collections
Related articles
- Small data sets to develop and validate prognostic models are problematic.
- Authors: Collins GS, Le Manach Y
- Issue date: 2016 Feb
- Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
- Authors: Valpione S, Martinoli C, Fava P, Mocellin S, Campana LG, Quaglino P, Ferrucci PF, Pigozzo J, Astrua C, Testori A, Chiarion-Sileni V
- Issue date: 2015 Sep
- Nivolumab success in untreated metastatic melanoma.
- Authors: Wilkinson E
- Issue date: 2015 Jan
- Prognostic score for patients with advanced melanoma treated with ipilimumab.
- Authors: Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J
- Issue date: 2015 Dec